Live Breaking News & Updates on Pvpi Pharmacovigilance Programme

Stay updated with breaking news from Pvpi pharmacovigilance programme. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Meftal painkiller: Meftal maker says adverse reaction flagged by IPC is very rare

Blue Cross Laboratories, the owner of the Meftal painkiller brand, has clarified that the adverse reaction the Indian Pharmacopoeia Commission (IPC) has flagged is a rare event. The company claims that the product s constituent, mefenamic acid, can cause adverse reactions, including eosinophilia and systemic symptoms (DRESS) syndrome. ....

United Kingdom , Pvpi Pharmacovigilance Programme , Indian Pharmacopoeia Commission , Blue Cross Laboratories , Across Laboratories , Pharmacovigilance Programme , Meftal Painkiller , Ipc Safety Alert , Indian Pharmacopoeia Commission Ipc ,